Roth Keeps TG Therapeutics (TGTX) as 'Focus Pick' Following ASCO Presentations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
TG Therapeutics, Inc. Announces Presentation of Single Agent Data for Both TG-1101 and TGR-1202 in Ongoing Phase I Clinical Studies
May 30, 2014 1:55 PM EDTHighlights from TG-1101 Data Include:
100% of CLL patients achieved a peripheral response with 67% achieving a partial response 44% of Indolent NHL patients achieved a complete response (22%) or partial response (22%) Well tolerated at highest doses tested, with infusion time averaging 90 minutes in later infusionsHighlights from TGR-1202 Data Include:
100% of evaluable CLL patients treated at 800 mg exhibited significant nodal reductions, with approximately 80% achieving a partial response or a nodal partial response with... More